BeOne Medicines (ONC) Gross Margin (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Gross Margin of 88.95% for Q1 2026, up 372.0% year-over-year from 18.85% in Q1 2025, and down 1.7% quarter-over-quarter from 90.49% in Q4 2025.
BeOne Medicines (ONC) Gross Margin (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Gross Margin for 10 consecutive years, with 88.95% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin rose 372.0% year-over-year to 88.95%; the TTM figure through Mar 2026 stood at 88.31% (up 350.0% YoY), while the FY2025 annual figure was 87.49%, up 308.0% from the prior year.
- Gross Margin retreated to 88.95% in Q1 2026 per ONC's latest filing, from 90.49% in the prior quarter.
- Across five years, Gross Margin topped out at 90.49% in Q4 2025 and bottomed at 78.72% in Q1 2022.
- Historically, Gross Margin has averaged 84.17% across 5 years, with a median of 83.87% in 2023.
- Annual changes were most pronounced in 2022 — Gross Margin slumped 1588 bps — and 2023, when it soared 742 bps.
- BeOne Medicines' Gross Margin stood at 80.66% in 2022, then increased by 3 bps to 83.32% in 2023, then advanced by 3 bps to 85.76% in 2024, then increased by 6 bps to 90.49% in 2025, then retreated by 2 bps to 88.95% in 2026.
- Business Quant data shows ONC's Gross Margin at 88.95% in Q1 2026, 90.49% in Q4 2025, and 86.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 80.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.76% |
| Mar 31, 2026 | 88.95% |
| Dec 31, 2025 | 90.49% |
| Sep 30, 2025 | 86.09% |
| Jun 30, 2025 | 87.49% |
| Mar 31, 2025 | 85.23% |
| Dec 31, 2024 | 85.76% |
| Sep 30, 2024 | 82.98% |
| Jun 30, 2024 | 85.13% |
| Mar 31, 2024 | 83.38% |
| Dec 31, 2023 | 83.32% |
| Sep 30, 2023 | 87.67% |
| Jun 30, 2023 | 83.87% |
| Mar 31, 2023 | 81.74% |
| Dec 31, 2022 | 80.66% |
| Sep 30, 2022 | 80.25% |
| Jun 30, 2022 | 79.16% |
| Mar 31, 2022 | 78.72% |
| Dec 31, 2021 | 77.31% |
| Sep 30, 2021 | 77.03% |